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Background. Although techniques of immunophenotyping have been successful in characterizing the cells in the cutaneous
infiltrates of mycosis fungoides little evidence suggests that variations in the phenotypic characterization correlate with prognosis.
Objectives. In a preliminary prospective, single-centre, study we correlated the T-cell phenotype in cutaneous biopsies with the
progression of the disease to determine whether the coexpression of CD4 and CD8 has an impact on prognosis. Methods. Skin
biopsy specimens from30newly diagnosed patientswere stainedwith immunoperoxidase techniques to determine their phenotypic
characteristics. After a median followup of 42 months patients were divided into two groups with stable and progressive disease.
Results. Eighteen patients had the conventional CD4+CD8− T-cell phenotype. Ten patients showed the coexpression of CD4 and
CD8 and had a slightly lower rate of progressive disease.Conclusions.The coexpression of CD4 and CD8 in cutaneous lesions is not
rare and is associated with a slightly lower rate of progressive disease. Since double positive CD4/CD8 phenotype is rarely reported
in mycosis fungoides the presence on conventional immunophenotyping of both CD may be due to a “mixture” of neoplastic cells
and inflammatory CD8+ tumor infiltrating lymphocytes. Immunohistochemical study combined with confocal microscopy could
clarify this issue.
1. Introduction
Mycosis fungoides (MF) represents the prototype of cuta-
neous T-cell lymphoma, which is defined as clonal expansion
of skin-homing T lymphocytes [1]. The natural history of
MF is characterized by an indolent progression through
four stages: patch, plaque, tumor, and visceral involvement.
The disease begins with lightly erythematous patches that
subsequently evolve into well-demarcated scaling plaques.
These plaques may then progress to tumor lesions and
subsequently spread to the viscera, but this progression is
not necessarily seen in all patients [2]. MF is classified into
clinical stages using the TNM classification. Previous studies
of prognostic indicators have shown that the skin (T) stage
and the presence or absence of extracutaneous disease are
the most important determinants of outcome. Patients with
limited skin involvement (T1) have a favorable prognosis,
whereas patients with tumor (T3) or erythrodermic MF
(T4) have an unfavorable prognosis [3, 4]. The diagnosis of
MF relies on histopathological examination of skin biopsies
[5]. Usually, MF is characterized by an infiltrate of 𝛼/𝛽 T
helper memory lymphocytes (𝛽F1+, CD3+, CD4+, CD5+,
CD8−, and CD45RO+) [1]. However, in a minority of cases
the neoplastic cells exhibit a T-cytotoxic (CD4−CD8+), 𝛾/𝛿
(𝛽F1−, CD3+, CD4−, CD5+, and CD8+) or a CD4/CD8
double-negative phenotype, that show no clinical and/or
prognostic differences [6]. Recently, a previously unrecog-
nized phenotype characterized by coexpression of CD4 and
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CD8 has been described [7, 8], but the influence of such
a phenotype on prognosis of MF has not been evaluated.
Therefore, although techniques of immunophenotyping have
been successful in characterizing the cells in the cutaneous
infiltrates of MF little evidence suggests that variations in the
phenotypic characterization correlate with prognosis.
In this preliminary prospective, single-centre study on a
limited number of patients with MF we correlated the T-cell
phenotype in cutaneous lesions with the progression of the
disease to determine whether the coexpression of CD4 and
CD8, compared to conventional CD4+CD8− phenotype, has
an impact on prognosis.
2. Patients and Methods
Patients with MF were prospectively included in this study
between January 2005 and December 2012, after giving
informed consent according to the declaration of Helsinki.
The diagnosis of MF was made according to the criteria of
the WHO-EORTC classification for cutaneous lymphomas
[1]. The clinical stage at presentation was determined using
the TNM classification adapted for MF [9]. Patients received
a comprehensive history and physical examination, complete
blood cell count including peripheral smear for Se´zary cells,
and general chemistry panel. Lesional cutaneous biopsies
were obtained in all patients upon admission into the study
before the start of therapy. Patients with clinically significant
adenopathy had their nodes evaluated by fine needle aspira-
tion or lymph node biopsy. When indicated, patient had an
extensive staging evaluation, including bonemarrow aspirate
and biopsy, and appropriate radiologic studies to determine
visceral involvement.
We included in the study only newly diagnosed patients
who had not previously received topical therapies (corticos-
teroids, topical nitrogen mustard, carmustine, and psoralen
with ultraviolet A), interferon, chlorambucil, methotrexate,
or polychemotherapy.
After initial evaluation, the patients were included into
a program of visits that were made every three months
throughout the period of followup. According to the course
of the disease and, more specifically, to their clinical status
at the time of the last clinical update, patients were classified
into two groups. The first group was formed by patients
with a progressive disease defined as the change to a more
advanced stage. In the second group patients who underwent
complete or partial remission and patients with stable disease
defined as presence ofMFwithout progressionwere included.
Factors associated with disease progression were studied
with special emphasis to T-cell phenotype. The study did
not consider the therapy received by the patients. Indeed
treatments were administered according to clinical stage and
were relatively homogeneous within each study group for
most of the patients, but no prospective therapeutic trial was
simultaneously performed. At early stages (I-IIa), most of
the patients were treated by topical therapies (corticosteroids,
topical nitrogen mustard, carmustine, and psoralen with
ultraviolet A). At advanced stages, radiotherapy was per-
formed on tumors, and interferon, chlorambucil, methotrex-
ate, or polychemotherapy was administered as needed.
3. Histopathologic and
Immunohistologic Analysis
Formalin fixed and paraffin-embedded tissues of lesional
cutaneous biopsies were obtained from all patients. Speci-
mens were fixed in 10% buffered formalin and subsequently
embedded in paraffin. Sections were stained with haema-
toxylin and eosin for routine histopathological evaluation.
The diagnosis of MF was established according to the criteria
proposed by Guitart et al. [10].
Immunostaining was performed on fixed, paraffin-
embedded tissue sections as previously described [11] using
monoclonal antibodies specific for T-cell associated antigens
(CD3, CD4, and CD8) and for B cell-associated antigens
(CD20).
4. Statistical Analysis
Statistical analysis was performed with dedicated STATA SE
12 (Stata Corporation, TX, USA). The Fisher’s exact test and
the Pearson 𝜒2-test were used to identify the differences
between the variables. A multivariate logistic regression was
used to evaluate the relationship among variables. Logistic
regression is a variation of ordinary regressionwhich predicts
the probability of the occurrence of a specific event as a
function of two or more independent variables. The results
obtainedwere expressed in terms of the odds ratio (OR) asso-
ciated with each predictor value, defined as the probability of
the event occurring divided by the probability of the event
not occurring. In all analyses, the cut-off level of statistical
significance was set at 0.05.
5. Results
Thirty patients (17 men and 13 women) with clinical and
histologic diagnosis of MF were included in the study. The
mean age at diagnosis was 64.5 years (range 49–78 years).
According to the TNM classification 8 patients were in stage
I, 13 in stage II, 6 in stage III, and 3 in stage IV. The thirteen
patients in stage II were classified as 6 stage IIa and 7 stage IIb.
Stages I-IIa were considered as early stages and stages IIb–IV
as advanced stages. At the time of diagnosis,MFwas in amore
advanced stage in women than men. Indeed, 52.9% of men
(versus 38.4% of women) were in early stages whereas 61.6%
of women (versus 47.1% of men) were in advanced stages.
Immunophenotypic analysis demonstrated that 93.3%
(28 out 30) of the patients with MF were CD4 positive.
CD20 was negative in all patients. Eighteen out 30 patients
had the mature CD4+/CD8− T-cell phenotype.The cytotoxic
T-cell phenotype CD4−/CD8+ was present in only one
patient as well as the CD4/CD8 double-negative phenotype.
Ten out of 30 patients (33.3%) had an immunophenotypic
profile characterized by the coexpression of CD4 and CD8.
When we compared the distribution of patients with the
coexpression and those with the conventional CD4+/CD8−
phenotype according to the TNM staging we could not
find any association between phenotypes and clinical stage.
Indeed the percentages of the patients with advanced stage,
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Table 1: Factors associated with the disease progression in patients with mycosis fungoides.
Disease progression Odds ratio Standard error 𝑧 𝑃 value 95% confidence interval
Phenotype 17,03 28,79 1,68 0,09 0,62 467,7
TNM stage 2,07 1,19 1,26 0,21 0,67 6,39
Duration of followup 1,19 0,16 1,31 0,19 0,91 1,55
Age at diagnosis 0,29 0,38 0,94 0,35 0,02 3,82
In the logistic regression model the dependent variable was the disease progression defined as the change to a more advanced stage; the independent variables
were T-cell phenotype (CD4+CD8+ vs CD4+CD8−), TNM stage at presentation, duration of followup, and age at diagnosis.
as compared with those in early stage, were not significantly
different in both groups (group CD4+/CD8− 50% versus
50%; group CD4+/CD8+ 40% versus 60%).
The median follow-up time in the study was 42 months
(ranging from 12 to 70 months) and was comparable among
the different clinical stages and phenotypes. None of the
patients died during the study period. At the end of the
followup 23 of 30 patients underwent complete or partial
remission or presented a stable disease without extension
of the lesions or increase of the number of lesions. Seven
patients showed a progressive disease defined as the change to
a more advanced stage. The age of patient at diagnosis (<65
years versus >65 years), the sex, the duration of symptoms
before diagnosis ofMF (<60months versus>60months), and
the TNM stage at presentation (early stages versus advanced
stages) were not associated with disease progression in
univariate as in multivariate analysis. The results of the
logistic regression analysis are reported inTable 1.None of the
independent variables introduced in the logistic regression
model was associated with disease progression defined as the
change to a more advanced stage. However, by analyzing the
distribution of T-cell phenotypes within the progressing and
nonprogressing groups we found that patients with the coex-
pressionCD4 andCD8had a slightly lower rate of progressive
disease as compared to patients with conventional phenotype
(10.0% versus 27.8%). In the logistic regression model the
value obtained by the independent variable phenotype has
almost reached the statistical significance (odds ratio 17.03,
𝑃 = 0.09, 95% confidence interval 0.62–467.7).
6. Discussion
In this preliminary prospective, single-centre study, we found
by conventional immunophenotyping a profile characterized
by the coexpression of CD4 and CD8 in one-third of patients
with MF. These patients showed a slightly lower rate of
progressive disease, compared to patients with conventional
CD4+/CD8− phenotype. These findings raise the possibility
that the coexpression of CD4 and CD8 in cutaneous lesions
may confer a better prognosis in MF.
In our patients the conventional T-helper phenotype
(CD4+/CD8−) was themost common (60% of patients), thus
confirming previous studies [1, 12]. Twelve patients had a
different phenotype. Two patients showed, respectively, the
cytotoxic phenotype (CD4−/CD8+) and the double negative
phenotype (CD4−/CD8−). The conventional immunostain-
ing in the remaining 10 patients (33.3%) showed the coexpres-
sion of CD4 and CD8.
The coexpression of CD4 and CD8 is an expected
event on common thymocytes, but it is fairly infrequent on
normal peripheral T lymphocytes. There is evidence that
in certain situations the normal CD4+ cells may coexpress
CD8 and interleukin-4 is able to induce the expression of
CD8 on T CD4+ clones [13]. Peripheral T lymphocytes with
CD4+/CD8+ phenotype have been described in some solid
and hematologic malignancies [14, 15]. However the double
positive CD4/CD8 phenotype is extremely rare in mycosis
fungoides [7, 8]. The findings of our patients may not be due
to the coexpression of both CD in the same neoplastic cell
but to the presence in the cutaneous lesions of a “mixture”
of neoplastic cells and inflammatory CD8+ tumor infiltrating
lymphocytes as previously demonstrated by Hoppe et al.
[16]. Immunohistochemical study combined with confocal
microscopy might clarify this issue as recently reported by
Tournier and coworkers [8] in a 31-year-old woman. In their
patient this technique revealed in lesional cutaneous biopsies
the coexpression of CD4 and CD8 in a subset of atypical T
lymphocytes.
In typical lesional biopsy specimens of MF other non-
neoplastic mononuclear cells are present including CD8+
tumor-infiltrating lymphocytes. The role that these cells play
in etiopathogenesis and natural history of MF is still unclear
[17].
In our patients with MF the subgroup with the coex-
pression of CD4 and CD8 has a slightly lower rate of
progressive disease in comparison to patients with conven-
tional CD4+/CD8− phenotype (10.0% versus 27.8%), and
in the logistic regression model the value obtained by the
independent variable T-cell phenotype has almost reached
the statistical significance.
This data might be of interest taking into account that
the limited number of patients and the median follow-up
period of just 3.5 years, although similar to those of other
investigations, may not allow adequate time for this indolent
lymphoma to progress.
The lower tendency to progression of disease in our
patients with the coexpression of CD4 and CD8 might be
related to increased activity of antitumor CD8+ lymphocytes
infiltrating the lesions. Our results may be consistent with
previous findings by Hoppe et al. [16] who demonstrated that
CD8+ tumor-infiltrating lymphocytes influenced the long-
term survival of patients with MF.
Another problem is the possibility that CD8+ inflam-
matory cells can appear in the course of treatment. This is
not the case of our patients because we have included in
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the present study only newly diagnosed patients who had
not previously received topical therapies (corticosteroids,
topical nitrogen mustard, carmustine, and psoralen with
ultraviolet A), interferon, chlorambucil, methotrexate, or
polychemotherapy.
Finally, in this preliminary prospective, single-centre
study, conventional immunophenotyping demonstrates the
coexpression of CD4 and CD8 in lesional cutaneous biop-
sies of one-third of patients with MF. These patients
show a slightly lower rate of progressive disease, compared
to patients with conventional CD4+/CD8− phenotype. A
prospective multicenter study on a larger population of
patients with a longer followup might be useful to confirm
if the coexpression of CD4 and CD8 may confer a better
prognosis in patients with MF.
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